Berman E, Kapelushnik J, Sharon I, Or R, Atlan H, Nagler A
Medical Biophysics Department, Hadassah University Hospital, Jerusalem, Israel.
Med Oncol. 1995 Jun;12(2):109-14. doi: 10.1007/BF01676711.
The use of proton high-resolution magnetic resonance spectroscopy (MRS) allows the rapid detection and quantitation of modification in the blood serum metabolic profiles in haematooncological patients. This study examines the feasibility of using proton MRS as a diagnostic tool in predicting the outcome of bone marrow transplantation (BMT) at the earliest possible date. Proton spectra of serum samples from 18 BMT patients (11 autologous-BMT and seven allogeneic-BMT), six hematooncological patients that did not undergo BMT and six normal individuals were recorded at 400 MHz. A longitudinal MRS study was carried for these groups and the data were evaluated for statistical significance. It was determined that the MRS results, taken at different time points before and after the BMT treatment, are statistically significant. However, no significant difference was observed in the MRS parameters between the transplanted patients and the control patients. We could not obtain significant correlation between the MRS results and the immunoglobulin level, engraftment parameters or the age, sex, stage of basic disease, conditioning protocols, transplant type, post transplant complications (including death) and outcome.
使用质子高分辨率磁共振波谱（MRS）能够快速检测和定量血液肿瘤患者血清代谢谱的变化。本研究探讨了尽早将质子MRS用作诊断工具以预测骨髓移植（BMT）结果的可行性。在400MHz下记录了18例BMT患者（11例自体BMT和7例异体BMT）、6例未接受BMT的血液肿瘤患者以及6例正常个体的血清样本的质子谱。对这些组进行了纵向MRS研究，并对数据进行统计学显著性评估。结果确定，在BMT治疗前后不同时间点获得的MRS结果具有统计学显著性。然而，移植患者与对照患者之间的MRS参数未观察到显著差异。我们未能在MRS结果与免疫球蛋白水平、植入参数或年龄、性别、基础疾病阶段、预处理方案、移植类型、移植后并发症（包括死亡）及结果之间获得显著相关性。
